1.A Case of Nivolumab-related Adrenal Cortical Insufficiency
Beibei WANG ; Xiaolin LI ; Caiying DU ; Jihong GENG ; Xianghua QUAN
Herald of Medicine 2025;44(5):814-816
This report presents a case of a 75-year-old patient with newly diagnosed gastric cancer,who had repeated symptoms of fatigue,confusion,and hyponatremia after 2 cycles of chemotherapy combined with nivolumab as neoadjuvant treat-ment and was later diagnosed with adrenal cortical insufficiency.After applying corticosteroid replacement therapy,there was im-provement,but cortisol remained low,and long-term corticosteroid therapy is needed.
2.Incidence and Mortality of Thyroid Cancer in Zhejiang Cancer Registration Areas in 2021 and Trends from 2000 to 2021
Caiying XIANG ; Ying CHEN ; Debing WANG ; Li XIE ; Huizhang LI ; Lingbin DU ; Mei LU ; Yanfei QIU
China Cancer 2025;34(10):756-763
[Purpose]To analyze the incidence and mortality of thyroid cancer in Zhejiang cancer registration areas in 2021 and trends from 2000 to 2021.[Methods]Based on cancer data from 22 registries across Zhejiang Province between 2000 and 2021,the crude incidence/mortality rates,age-standardized incidence/mortality rates of thyroid cancer by Chinese and world standard population(ASIRC/ASMRC,ASIRW/ASMRW),cumulative rate(0~74 years old)and truncated rate(35~64 years old)were analyzed.Joinpoint regression model was employed to calculate the annual percentage change(APC)and average annual percentage change(AAPC)with 95%confidence in-terval(CI)for analyzing trends of thyroid cancer incidence and mortality rates from 2000 to 2021.[Results]The crude incidence rate of thyroid cancer increased from 3.62/105 in 2000 to 79.66/105 in 2021,and ASIRC rose from 3.11/105 to 69.49/105(AAPC=15.55%,95%CI:14.65%~16.61%).The AAPC for ASIRC was slightly higher in female(15.54%,95%CI:14.71%~16.49%)than that in male(15.02%,95%CI:13.53%~16.82%).The increase was significantly more pronounced in rural areas(AAPC=23.34%,95%CI:21.48%~25.33%)compared to urban areas(AAPC=14.12%,95%CI:13.15%~15.43%).Among age groups,the age group of 15~44 years old showed the fastest increase in crude incidence rate(AAPC=20.37%,95%CI:18.46%~22.31%),followed by the age group of 45~64 years old(AAPC=18.41%,95%CI:16.65%~20.19%).Between 2000 and 2021,the crude mortality rate of thyroid cancer rose from 0.34/105 to 0.56/105(AAPC=5.52%,95%CI:3.45%~7.70%),the trend of ASMRC was relatively stable.[Conclusion]From 2000 to 2021,the incidence of thyroid cancer in Zhejiang Province increased markedly,especially among females and younger to middle-aged adults,while the age-standardized mortality rate remained stable.
3.Incidence and Mortality of Thyroid Cancer in Zhejiang Cancer Registration Areas in 2021 and Trends from 2000 to 2021
Caiying XIANG ; Ying CHEN ; Debing WANG ; Li XIE ; Huizhang LI ; Lingbin DU ; Mei LU ; Yanfei QIU
China Cancer 2025;34(10):756-763
[Purpose]To analyze the incidence and mortality of thyroid cancer in Zhejiang cancer registration areas in 2021 and trends from 2000 to 2021.[Methods]Based on cancer data from 22 registries across Zhejiang Province between 2000 and 2021,the crude incidence/mortality rates,age-standardized incidence/mortality rates of thyroid cancer by Chinese and world standard population(ASIRC/ASMRC,ASIRW/ASMRW),cumulative rate(0~74 years old)and truncated rate(35~64 years old)were analyzed.Joinpoint regression model was employed to calculate the annual percentage change(APC)and average annual percentage change(AAPC)with 95%confidence in-terval(CI)for analyzing trends of thyroid cancer incidence and mortality rates from 2000 to 2021.[Results]The crude incidence rate of thyroid cancer increased from 3.62/105 in 2000 to 79.66/105 in 2021,and ASIRC rose from 3.11/105 to 69.49/105(AAPC=15.55%,95%CI:14.65%~16.61%).The AAPC for ASIRC was slightly higher in female(15.54%,95%CI:14.71%~16.49%)than that in male(15.02%,95%CI:13.53%~16.82%).The increase was significantly more pronounced in rural areas(AAPC=23.34%,95%CI:21.48%~25.33%)compared to urban areas(AAPC=14.12%,95%CI:13.15%~15.43%).Among age groups,the age group of 15~44 years old showed the fastest increase in crude incidence rate(AAPC=20.37%,95%CI:18.46%~22.31%),followed by the age group of 45~64 years old(AAPC=18.41%,95%CI:16.65%~20.19%).Between 2000 and 2021,the crude mortality rate of thyroid cancer rose from 0.34/105 to 0.56/105(AAPC=5.52%,95%CI:3.45%~7.70%),the trend of ASMRC was relatively stable.[Conclusion]From 2000 to 2021,the incidence of thyroid cancer in Zhejiang Province increased markedly,especially among females and younger to middle-aged adults,while the age-standardized mortality rate remained stable.
4.A Case of Nivolumab-related Adrenal Cortical Insufficiency
Beibei WANG ; Xiaolin LI ; Caiying DU ; Jihong GENG ; Xianghua QUAN
Herald of Medicine 2025;44(5):814-816
This report presents a case of a 75-year-old patient with newly diagnosed gastric cancer,who had repeated symptoms of fatigue,confusion,and hyponatremia after 2 cycles of chemotherapy combined with nivolumab as neoadjuvant treat-ment and was later diagnosed with adrenal cortical insufficiency.After applying corticosteroid replacement therapy,there was im-provement,but cortisol remained low,and long-term corticosteroid therapy is needed.
5.Research progress of dalpiciclib in treatment of breast cancer
Caiying DU ; Xianghua QUAN ; Caihong SUN ; Haidan YUAN
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(6):715-720
As the first domestically originated cell cycle protein-dependent kinase 4/6 inhibitor,dalpiciclib has been approved by the State Drug Ad-ministration for the treatment of hormone recep-tor-positive/human epidermal growth factor recep-tor 2-negative advanced or metastatic breast can-cer in combination with fulvestrant or aromatase inhibitors.This article focuses on the progress of dalpiciclib research in breast cancer,summarizing the drug's mechanism of action,phase Ⅰ-Ⅲ clinical trials,and drug safety issues.
6.Detection trend of vaginal intraepithelial neoplasia diagnosed by colposcopy guided biopsy from 2013 to 2015
Qing CONG ; Qing WANG ; Shujun GAO ; Hongwei ZHANG ; Ming DU ; Feng XIE ; Jing DONG ; Hua FENG ; Ruilian ZHENG ; Min CHEN ; Caiying ZHU ; Wenjing DIAO ; Yu SONG ; Qisang GUO ; Yanyun LI ; Limei CHEN ; Yuankui CAO ; Long SUI
Chinese Journal of Obstetrics and Gynecology 2017;52(4):239-243
Objective To explore the detection trend of vaginal intraepithelial neoplasia(VaIN)of lower genital tract from 2013 to 2015. Methods A retrospective analysis was undertaken of colposcopy-directed biopsy of cervical, vaginal and vulvar intraepithelial neoplasia lesions include cervical intraepithelial neoplasia (CIN), VaIN and vulvar intraepithelial neoplasia (VIN) in Obstetrics and Gynecology Hospital of Fudan University from January 2013 to December 2015. Results (1) Overall data of CIN, VaIN and VIN:a total of 16732 cases were diagnosed of lower genital intraepithelial neoplasia in 3 years, accounting for 23.20% (16732/72128) of total colposcopy-directed biopsy cases. Among them, CIN, VaIN and VIN accounted for 19.48%(14053/72128), 2.67%(1923/72128), 1.05%(756/72128) of total colposcopy-directed biopsy cases of the lower genital tract, 83.99%(14053/16732), 11.49%(1923/16732), 4.52%(756/16732) of total lower genital intraepithelial neoplasia, respectively. (2) Annual data of CIN, VaIN and VIN from 2013 to 2015. The annual proportion of CIN in all intraepithelial neoplasia of lower gential tract was basically stable, consisting of 86.02%(3955/4598),83.25%(4795/5760) and 83.20%(5303/6374), respectively. The annual proportion of VaIN was gradually increasing, consisting of 8.09% (372/4598), 12.45%(717/5760) and 13.08%(834/6374), respectively. The annual proportion of VIN was gradually decreasing, consisting of 5.89% (271/4598), 4.31% (248/5760) and 3.72% (237/6374), respectively. Conclusion The increasing detection of VaIN from 2013 to 2015 might correlate with the increasing attention to inspection of the entire vaginal wall.
7.Evaluation scales for doctor-patient communication in general practice
Meirong WANG ; Dandan ZHANG ; Yingjie LIU ; Caiying GE ; Juan DU
Chinese Journal of General Practitioners 2017;16(12):969-972
Communication skills are the basic requirement for general practitioners,the continuous improvement of communication skills is the guarantee of the service quality.It is crucial to establish an effective evaluation system in the training of communication skills for general practitioners.This article reviews the current status of evaluation scales of doctor-patient communication skill commonly used in China and other countries to provide reference for the establishment of the communication skill evaluation system for general practitioners which is suitable for China's condition.

Result Analysis
Print
Save
E-mail